High-yield production of pBR322-derived plasmids intended for human gene therapy by employing a temperature-controllable point mutation

被引:65
作者
Lahijani, R
Hulley, G
Soriano, G
Horn, NA
Marquet, M
机构
[1] Vical, Incorporated, San Diego
[2] Vical Inc., San Diego, CA 92121
关键词
D O I
10.1089/hum.1996.7.16-1971
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Production of large quantities of highly purified plasmid DNA is essential for gene therapy, A low-copy-number pBR322-derived plasmid (VCL1005) was converted to a high-copy-number plasmid (VCL1005G/A) by incorporating a G --> A mutation that affects initiation of DNA replication from the ColE1 origin of replication, Because the phenotypic effect of this mutation is enhanced at an elevated temperature, a further increase in yield was achieved by changing the growth temperature from 37 degrees C to 42 degrees C at mid-log phase during batch and fed-batch fermentation, The combined effect of the single base-pair change and the elevated growth temperature produced an overall yield of 2.2 grams of plasmid DNA available for recovery from a 10-liter fed-batch fermentation compared to 0.03 grams from a 10-liter batch fermentation, a 70-fold increase in yield, The plasmid DNA isolated from this process contained lower levels of RNA and chromosomal DNA contaminants, simplifying downstream processing.
引用
收藏
页码:1971 / 1980
页数:10
相关论文
共 41 条
[11]  
FELGNER JH, 1994, J BIOL CHEM, V269, P2550
[12]  
FELGNER PL, 1990, ADV DRUG DELIVERY RE, V5, P167
[13]   PRODUCTION OF HUMAN ALPHA-CONSENSUS INTERFERON IN RECOMBINANT ESCHERICHIA-COLI [J].
FIESCHKO, J ;
RITCH, T .
CHEMICAL ENGINEERING COMMUNICATIONS, 1986, 45 (1-6) :229-240
[14]   CONDITIONAL HIGH COPY NUMBER COLE1 MUTANTS - RESISTANCE TO RNA1 INHIBITION INVIVO AND INVITRO [J].
FITZWATER, T ;
ZHANG, XY ;
ELBLE, R ;
POLISKY, B .
EMBO JOURNAL, 1988, 7 (10) :3289-3297
[15]  
Herman Anna, 1994, Acta Biochimica Polonica, V41, P122
[16]   CANCER GENE-THERAPY USING PLASMID DNA - PURIFICATION OF DNA FOR HUMAN CLINICAL-TRIALS [J].
HORN, NA ;
MEEK, JA ;
BUDAHAZI, G ;
MARQUET, M .
HUMAN GENE THERAPY, 1995, 6 (05) :565-573
[17]   HIGH-CELL DENSITY FERMENTATION STUDIES OF RECOMBINANT ESCHERICHIA-COLI STRAINS EXPRESSING HUMAN INTERLEUKIN-1-BETA [J].
JUNG, G ;
DENEFLE, P ;
BECQUART, J ;
MAYAUX, JF .
ANNALES DE L INSTITUT PASTEUR-MICROBIOLOGIE, 1988, 139 (01) :129-146
[18]   NONVIRAL GENE-THERAPY - THE PROMISE OF GENES AS PHARMACEUTICAL PRODUCTS [J].
LEDLEY, FD .
HUMAN GENE THERAPY, 1995, 6 (09) :1129-1144
[19]   CANCER GENE-THERAPY USING PLASMID DNA - PHARMACOKINETIC STUDY OF DNA FOLLOWING INJECTION IN MICE [J].
LEW, D ;
PARKER, SE ;
LATIMER, T ;
ABAI, AM ;
KUWAHARARUNDELL, A ;
DOH, SG ;
YANG, ZY ;
LAFACE, D ;
GROMKOWSKI, SH ;
NABEL, GJ ;
MANTHORPE, M ;
NORMAN, J .
HUMAN GENE THERAPY, 1995, 6 (05) :553-564
[20]   HIGH COPY NUMBER OF THE PUC PLASMID RESULTS FROM A ROM ROP-SUPPRESSIBLE POINT MUTATION IN RNA-II [J].
Lin-Chao, S ;
CHEN, WT ;
WONG, TT .
MOLECULAR MICROBIOLOGY, 1992, 6 (22) :3385-3393